Package 49702-202-18

{"route": ["ORAL"], "spl_id": "42a6587e-9322-4810-8c72-1dc40f3543d2", "openfda": {"nui": ["N0000175656", "N0000175462", "N0000009947"], "upc": ["0349702202184"], "unii": ["2T8Q726O95", "4B9XT59T7S"], "rxcui": ["200082", "213088"], "spl_set_id": ["16da660b-9981-4d24-a14a-94c7744fce4f"], "pharm_class_epc": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["ViiV Healthcare Company"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "60 TABLET, FILM COATED in 1 BOTTLE (49702-202-18)", "package_ndc": "49702-202-18", "marketing_end_date": "20270228", "marketing_start_date": "20101019"}], "brand_name": "COMBIVIR", "product_id": "49702-202_42a6587e-9322-4810-8c72-1dc40f3543d2", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "product_ndc": "49702-202", "generic_name": "lamivudine and zidovudine", "labeler_name": "ViiV Healthcare Company", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "COMBIVIR", "active_ingredients": [{"name": "LAMIVUDINE", "strength": "150 mg/1"}, {"name": "ZIDOVUDINE", "strength": "300 mg/1"}], "application_number": "NDA020857", "marketing_category": "NDA", "marketing_end_date": "20270228", "marketing_start_date": "20101019"}